✦ LIBER ✦

INCIDENCE OF CHOLINERGIC AND MEMANTINE TREATMENT IN ALZHEIMER'S DISEASE IN FINLAND

✍ Scribed by Lauri Virta; Petteri Viramo

Book ID: 109129732
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 83 KB
Volume: 55
Category: Article
ISSN: 0002-8614
DOI: 10.1111/j.1532-5415.2007.01383.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Neuropharmacological Basis for the U

The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease

✍ Michael A. Rogawski; Gary L. Wenk 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 519 KB

Cholinergic neuropathology in a mouse mo

Cholinergic neuropathology in a mouse model of Alzheimer's disease

✍ Dwight C. German; Umar Yazdani; Samuel G. Speciale; Parichehr Pasbakhsh; Dora Ga 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 836 KB

Memantine enhances autonomy in moderate

Memantine enhances autonomy in moderate to severe Alzheimer's disease

✍ Benoît Rive; Martine Vercelletto; Florence Delamarre Damier; John Cochran; Cléme 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

## Abstract ## Background Alzheimer's disease (AD) is the leading cause of dementia and its course renders patients functionally disabled. Memantine is the first drug to demonstrate a clinical benefit in the treatment of patients with moderately‐severe to severe AD. ## Objectives Our objective w

Incidence of clinically confirmed farmer

Incidence of clinically confirmed farmer's lung disease in Finland

✍ Erkki O. Terho; Olli P. Heinonen; Seppo Lammi 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

The place of memantine in the treatment

The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis

✍ Gill Livingston; Cornelius Katona 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 1 views

## Abstract ## Introduction Memantine is currently the only treatment approved for moderately severe to severe Alzheimer's disease (AD). There is still some discussion as to its place in clinical practice and many UK clinicians are discouraged for economic reasons from prescribing it. We adopt a ‘

Tolerability of switching from donepezil

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

✍ Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki L 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 44 KB 👁 2 views

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving